Clinical Profile and Risk Factors for Severe COVID-19 in Hospitalized Patients from Rio de Janeiro, Brazil: Comparison between the First and Second Pandemic Waves

J Clin Med. 2023 Mar 29;12(7):2568. doi: 10.3390/jcm12072568.

Abstract

Since COVID-19 was declared a pandemic, Brazil has become one of the countries most affected by this disease. A year into the pandemic, a second wave of COVID-19 emerged, with a rapid spread of a new SARS-CoV-2 lineage of concern. Several vaccines have been granted emergency-use authorization, leading to a decrease in mortality and severe cases in many countries. However, the emergence of SARS-CoV-2 variants raises the alert for potential new waves of transmission and an increase in pathogenicity. We compared the demographic and clinical data of critically ill patients infected with COVID-19 hospitalized in Rio de Janeiro during the first and second waves between July 2020 and October 2021. In total, 106 participants were included in this study; among them, 88% had at least one comorbidity, and 37% developed severe disease. Disease severity was associated with older age, pre-existing neurological comorbidities, higher viral load, and dyspnea. Laboratory biomarkers related to white blood cells, coagulation, cellular injury, inflammation, renal, and liver injuries were significantly associated with severe COVID-19. During the second wave of the pandemic, the necessity of invasive respiratory support was higher, and more individuals with COVID-19 developed acute hepatitis, suggesting that the progression of the second wave resulted in an increase in severe cases. These results can contribute to understanding the behavior of the COVID-19 pandemic in Brazil and may be helpful in predicting disease severity, which is a pivotal for guiding clinical care, improving patient outcomes, and defining public policies.

Keywords: COVID-19; epidemic waves; epidemiology; risk factors.

Grants and funding

This research was funded by L.AAL, supported by FAPERJ (E-26/201.406/2021), MS/Programa Inova FIOCRUZ—Edital Geração de Conhecimento—Enfrentamento da Pandemia e Pós-pandemia COVID-19: Encomendas Estratégicas”/processo VPPCB-005-FIO-20-2-56); S.V.A.-L. is supported by FAPERJ (E-26/210.254/2020–Edital Segunda Chamada Emergencial de Projetos para Combater os Efeitos da COVID-19–2020, E-26/210.657/2021, E-26/210.273/2018 and E-26/201.040/2021); F.L.F.D. is supported by FAPERJ (E-26/202.021/2020) and Edital Prociência 2022 UERJ; V.S.P and L.A.A L are supported by FAPERJ (E-26/210.817/2021) Edital Afecções pós-COVID and CNPq 403008/2021-2; R.A.M. is supported by FAPERJ (E-26/210.192/2020, E-26/210.166/2020 and E-26/201.243/2021). We are also thankful to Coordination for the Improvement of Higher Education Personnel—CAPES for the fellowship awarded.